Skip to main content
. Author manuscript; available in PMC: 2013 Apr 3.
Published in final edited form as: Methods Cell Biol. 2011;105:383–402. doi: 10.1016/B978-0-12-381320-6.00016-3

Figure 2.

Figure 2

Assessing collaborating genetic events that modify time to ERMS onset in mosaic transgenic zebrafish. A) Schematic demonstrating injection of oncogenic rag2-kRASG12D into embryos with p53 alterations. P53 loss accelerates time to tumor onset and overall numbers of animals that develop ERMS. B) Schematic demonstrating injection strategy to determine the effect of noxa on p53 pathway in kRAS-induced zebrafish rhabdomyosarcoma. In these experiments, tumor onset is assessed by the development of externally visible tumors and then animals from each genotype are compared by Kaplan-Meier survival analysis (bottom). Noxa suppresses tumor onset in p53-deficient animals.